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Cellular inhibitor of apoptosis (cIAP) proteins, cIAP1 and
cIAP2, are important regulators of tumor necrosis factor (TNF)
superfamily (SF) signaling and are amplified in a number of
tumor types. They are targeted by IAP antagonist compounds
that are undergoing clinical trials. IAP antagonist compounds
trigger cIAP autoubiquitylation and degradation. The TNFSF
member TWEAK induces lysosomal degradation of TRAF2 and
cIAPs, leading to elevated NIK levels and activation of non-ca-
nonical NF-B. To investigate the role of the ubiquitin ligase
RINGdomain of cIAP1 in these pathways,weused cIAP-deleted
cells reconstituted with cIAP1 point mutants designed to inter-
fere with the ability of the RING to dimerize or to interact with
E2 enzymes. We show that RING dimerization and E2 binding
are required for IAP antagonists to induce cIAP1 degradation
and protect cells fromTNF-induced cell death. The RING func-
tions of cIAP1 are required for full TNF-induced activation of
NF-B, however, delayed activation of NF-B still occurs in
cIAP1 and -2 double knock-out cells. The RING functions of
cIAP1 are also required to prevent constitutive activation of
non-canonical NF-B by targeting NIK for proteasomal degra-
dation. However, in cIAP double knock-out cells TWEAK was
still able to increase NIK levels demonstrating that NIK can be
regulated by cIAP-independent pathways. Finally we show that,
unlike IAP antagonists, TWEAKwas able to induce degradation
of cIAP1 RING mutants. These results emphasize the critical
importance of the RING of cIAP1 in many signaling scenarios,
but also demonstrate that in some pathways RING functions are
not required.
Cellular inhibitors of apoptosis (cIAPs)5 were identified as
proteins that bound directly to the adaptor protein TRAF2,
which in turn binds to tumor necrosis factor receptor 2 (TNF-
R2) (1). cIAPs have three baculoviral IAP repeat domains and
interaction of cIAP1 with TRAF2 is dependent on residues
within the N-terminal, baculoviral IAP repeat 1 (BIR1) (2, 3).
cIAP1 and cIAP2 also bear a C-terminal RING E3 ligase
domain, and it is this domain that is required for IAP antagonist
compound (IAC)-induced autoubiquitylation and proteasomal
degradation (4–7). cIAPs control activation of the NF-B fam-
ily of transcription factors in both unstimulated and cytokine-
treated cells. In the absence of cytokines, together with TRAF2
and TRAF3, cIAPs ubiquitylate and promote proteasomal deg-
radation of NF-B inducing kinase (NIK), thereby preventing
NIK from activating NF-B2. Consistent with a central role for
cIAPs in these processes, antagonism of IAPs by IACs is suffi-
cient to activate the non-canonical NF-B pathway through
NIK stabilization and processing of p100 to p52 (6–9).
TNF-like weak inducer of apoptosis (TWEAK) binding to its
receptor Fn14 is a physiological activator of NF-B. Receptor
engagement results in lysosomal mediated degradation of
TRAF2 and cIAP1 and activation of non-canonical NF-B
resulting from NIK stabilization and subsequent processing of
p100 to the active NF-B subunit p52 (7, 10, 11). In support of
this idea, TRAF2 or cIAP1 knock-outMEFswere shown to have
high constitutive levels of p52 and low levels of p100 compared
with wild-type cells (6, 12). cIAPs also play an important role at
the TNF-R1 signaling complex in TNF-induced activation of
canonical NF-B. RIPK1 ubiquitylation can contribute to acti-
vation of canonical NF-B by recruiting NEMO-IKK1-IKK2
and TAB2-TAK1, initiating a signaling cascade leading to
translocation of p65-RelANF-B subunits to the nucleus, how-
ever, RIPK1 is not essential for TNF-induced NF-B (13). The
E3 ligase responsible for RIPK1 ubiquitylation is still not clear;
IAPs are an attractive candidate because loss of cIAPs by either
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IAC treatment, small interfering RNA knockdown or disrup-
tion of both genes significantly inhibits RIPK1 ubiquitylation
(14–17). However, interestingly some minor ubiquitylation of
RIPK1 in TNF-stimulated cells can still be seen even in the
absence of cIAPs, suggesting other E3 ligases are involved (18).
Several new E3 ligases have recently been reported to play a
role in activating NF-B. RNF11 was shown to play a role in the
recruitment of A20 to RIPK1 and thereby negatively regulate
NF-B and c-Jun N-terminal kinase (JNK) signaling (19). The
RING E3 ligases HOIL-1 and HOIP are also required for a sus-
tained TNF-induced NF-B signal (17, 20). Subtle differences
in response from the E3 ligases followingTNFmight also be cell
type dependent, a result from the different forms of available
TNF (membrane bound or soluble), or even due to their effects
on other signaling pathways. Nevertheless, it is clear that
removal of cIAPs sensitizes many different cell types to TNF-
induced death.
Although the mechanism is still unclear, it appears that
RING dimerization is important for E3 ligase function. Struc-
tural studies have revealed RING domain homodimers for
many E3 ligases, including MDM2, MDMX, cIAP2, and RAG1
(5, 21, 22) and several RINGs, such asMDM2-MDMX,BRCA1-
BARD1, and XIAP-cIAP1 can heterodimerize (22–27). Con-
sistent with an important role for dimerization in RING func-
tion, cIAP RING dimerization is required for IAC-induced
degradation of cIAP1 (5, 27). RING domains are required to
recruit UBC E2 enzymes to substrates and cIAP1 has been
shown by several groups to recruit UbcH5 (16, 27–29).
We generated point mutations in the baculoviral IAP repeat
1 (BIR1) of cIAP1 that specifically affect binding by TRAFs, as
well asmutations in the RING that prevent dimerization and E2
binding. Thesemutations abolish the ability of cIAP1 to protect
cells fromTNF-induced apoptosis. These mutations also inter-
fere with the ability of cIAP1 to activate canonical NF-B in
response to TNF, and destroy the regulation of non-canonical
NF-B by cIAP1. Interestingly, TWEAK-induced degradation
of cIAP1was not affected by these RINGmutations indicating a
significantly different role for cIAP1 at different TNFSF
receptors.
EXPERIMENTAL PROCEDURES
Transient Transfections, Antibodies, and Reagents—Tran-
sient transfections, typically using 1g of plasmid DNA/10-cm
plate of cells, were performed with EffecteneTM according to
the manufacturer’s instructions (Qiagen). Antibodies were
used as follows: monoclonal anti- actin (Sigma), polyclonal
mouse anti-TRAF2, 1:1000 (Santa Cruz); monoclonal anti-
cIAP1, 1:500 (Alexis); polyclonal anti-p65, 1:1000 (Western
blotting) and 1:100 (immunostaining) (Santa Cruz); polyclonal
anti-p100-p52, 1:1000 (Cell Signaling); polyclonal anti-IB,
1:1000 (Santa Cruz); polyclonal anti-NIK, 1:1000 (Cell Signal-
ing); anti-FLAG, 1:2000 (Sigma); anti-ubiquitin, 1:1000 (Cell
Signaling); fluorescein isothiocyanate-conjugated anti-rabbit,
1:500 (Invitrogen). 4-Hydroxytamoxifen (4HT, Sigma) was
used at concentrations ranging from 5 to 100 nM. The IAP
antagonist, compoundA, has previously been described (6) and
was used at 500 nM.
Cell Culture and Lentivirus Production—All cell lines were
maintained in Dulbecco’s modified Eagle’s medium supple-
mented with 8–10% fetal bovine serum, 2 mM L-glutamine and
penicillin/streptomycin, and grown at 37 °C, 10% CO2. To gen-
erate lentiviral particles, 293T cells were transfected with pack-
aging constructs pCMV R8.2, pVSVg, and at a relevant lenti-
viral plasmid ratio of 1:0.4:0.6. After 24 h the virus containing
supernatants were harvested and filtered (0.8 M). Target cells
were infected with virus supernatant for 24 h. Themediumwas
subsequently changed and successful infection was selected
with puromycin (5g/ml, pF 5UAS selection) or hygromycin
B (300 g/ml, GEV16 selection). pF 5 UAS inducible con-
structs were induced with 4HT for 16 h prior to lysate harvest-
ing forWestern blotting or 72 h (5–10 nM) prior to death assays.
Constructs—Inducible mouse cIAP1 wild-type and cIAP1
F610A cloned into pF 5UAS SV40 Puro have been previously
described (5). Mouse cIAP1 E2 binding mutants V567A/
D570A, L593A/I598A, L593A, and V567A were generated by
spliced overlap PCR mutagenesis and cloned into the pF 5
UAS SV40 Puro vector using standard techniques and con-
firmed by sequencing. The Ubc13 shRNA andGFP shRNA len-
tiviral vectors were a kind gift from Dr. M. A. Kelliher (Univer-
sity orMassachusetts). Complete sequence of all constructs can
be obtained upon request.
Generation of MEFs—Generation of MEFs has been
described in detail elsewhere (6, 10). Briefly, primary MEFs
were generated from embryos using standard protocols and
then infectedwith SV40 large T antigen expressing lentivirus to
generate immortal cell lines. Double knock-out cIAP1 and
cIAP2 MEFs (DKO) were obtained from a cIAP1LoxP/LoxP and
cIAP2FRT/FRT mouse crossed with a Cre transgenic and the
resulting progeny were backcrossed to generate cIAP1/-
cIAP2FRT/FRT mice. These mice were subsequently crossed
with Flp transgenic mice to generate cIAP1/cIAP2/
(DKO) mice in the same manner. DKO MEFs were generated
using E10 embryos rather than E15 embryos. TheseMEFs were
also immortalized with SV40 large T expressing lentivirus.
Immortal cIAP1/MEFs from E15 embryos obtained from a
cIAP1LoxP/LoxPcIAP2FRT/FRT, Cre transgenic cross were gener-
ated in the same manner.
Death Assays—Cells were seeded on 12-well tissue culture
plates at40% confluence and allowed to adhere for 16–20 h.
Cells were incubatedwith orwithout 4HT for 72 (MEFs) or 24 h
(D645s and Kym1s) and then human Fc-TNF (100 ng/ml) or
humanFc-TWEAK (100ng/ml)were added to cells for 24 h and
cell death was measured by propidium iodide staining and flow
cytometry. In each sample, 5000 events weremeasured and cell
death (% propidium iodide positive cells) was quantified.
Western Blotting—Samples were lysed in DISC lysis buffer
containing 1% Triton X-100 supplemented with protease
inhibitormixture (RocheApplied Science) andN-ethylmaleim-
ide (NEM) on ice for 30 min and clarified by centrifugation.
Alternatively, for whole cell lysates, samples were boiled in the
presence of 1% SDS and sheared through a 19-gauge needle.
Samples were separated on precast 4–20% polyacrylamide gels
(Bio-Rad) and transferred to nitrocellulose membranes for
antibody detection. All membrane blocking steps and antibody
dilutions were performed with 5% skimmilk in PBS containing
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0.1% Tween 20 (PTBS), and washing steps performed with
PTBS. Proteins on Western blots were visualized by ECL
(Amersham Biosciences) following incubation of membranes
with horseradish peroxidase-coupled secondary antibodies.
Immunostaining—Cells were grown on 25-mm coverslips
overnight. Cells were treated as indicated and fixed immedi-
ately with 3% paraformaldehyde for 30 min and washed three
times with PBS. Cells were incubated with 150mM glycine/PBS
for 15 min to block amine groups, and washed three times with
PBS. Cells were permeablized with
0.5% Triton X-100/PBS for 5 min
and washed three times with PBS.
Cells were blocked in 1% bovine
serum albumin/PBS for 30min sub-
sequent to incubation with poly-
clonal p65 antibody (1:100) (Santa
Cruz) for 30min. Cells were washed
four times and incubated with fluo-
rescein isothiocyanate-conjugated
secondary anti-rabbit antibody
(1:500) (Invitrogen) for 30 min.
Cells were washed three times with
PBS. The coverslips were then
mounted to slides with Polymount
(anti-fade) and sealed with nail pol-




dation of cIAP1 Requires E2 Binding
and RINGDimerization—Using the
crystal structure of the RING
domain of cIAP2 bound to the E2
UbcH5 (5), we identified residues
that were likely to be important for
RING dimerization and interaction
with the E2 enzyme. The F610A
mutant prevents cIAP1RINGdimer
formation and has been previously
described (5). Point mutations at
positionsVal567, Asp570, Leu593, and
Ile598 in mouse cIAP1 were intro-
duced to disrupt E2 enzyme
binding.
To investigate the features of the
RING domain required for IAP
antagonist-induced degradation we
reintroduced these cIAP1 RING
mutants into cIAP1/MEFs using
an inducible lentiviral system,
achieving close to endogenous lev-
els (Fig. 1B, cf. lane 2with lanes 5, 8,
11, 14, and 17). Single mutations
such as Val567 or Leu593 alone were
able to partially protect cIAP1 from
IAC degradation (5). Double muta-
tions at either Val567 and Asp570 or
Leu593 and Leu598 were, however, more effective at protecting
cIAP1 from IAC-induced degradation, with V567A/D570A
being slightly less effective than L593A/I598A (Fig. 1B, lanes 9
and 12). As previously described, the F610A mutant that dis-
rupts dimer formation was resistant to IAP antagonist (com-
pound A (6)) induced degradation (Fig. 1B, lane 15 (5). IAP
antagonist compounds also trigger the autoubiquitylation of
IAPs, which provides the signal for their degradation via the
proteasomal pathway (7). Consistent with our RING mutants
FIGURE 1. RING mutants of cIAP1 are resistant to compound A-induced degradation. A, a schematic
representation of the crystal structure of the cIAP2 RING domain (red) bound to UbcH5b (blue) overlaid on a
surface representation of the structure with E2 interacting residues Val559 and Asp562 and the dimer interface
residues highlighted in yellow and stick form. The equivalent cIAP1 residues are indicated in the box. B, E2
binding anddimer formation are required for IAP antagonist-induced degradation cIAP1. cIAP1/MEFswere
immortalized with SV40 large T and infected with a lentivirus expressing inducible cIAP1 constructs. Single
clones expressingwild-type or pointmutants in the dimerization (F610A) or E2 binding (V567A, D570A, L593A,
I598A) interface were generated. Clones were simultaneously induced with 5 nM 4HT and treated with or
without 500 nM compound A (6) for 16 h. Cells were lysed in DISC lysis buffer supplemented with protease
inhibitors and NEM. Lysates were separated using SDS-PAGE and blotted with a cIAP1 antibody.
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being resistant to IAC-induced degradation, they were also not
ubiquitylated following IAC treatment (supplemental Fig. S1A,
cf. lanes 4, 8, and 12). These results show that targeted muta-
tions that inhibit either E2 binding or RING dimerization
prevent IAP antagonist-induced ubiquitylation and degrada-
tion of IAPs.
TWEAK Induces Degradation of cIAP1 RINGMutants—The
TNFSF ligand TWEAK triggers lysosomal degradation of
cIAP1 and TRAF2, whereas IAP antagonists induce proteaso-
mal degradation of cIAP1 (4, 6, 7, 10, 15, 30). It was therefore
interesting to ask whether the RING activity of cIAP1 was also
required for TWEAK-induced lysosomal degradation of cIAP1.
As previously reported TWEAK-induced cIAP1 degradation
was less complete compared with degradation induced by our
IAP antagonist compound (e.g. Fig. 2A, cf. lanes 3 and 4 (10)).
IAP antagonist-treated cells were included as an internal con-
trol, and consistent with our observations in Fig. 1A our dimer-
ization mutant (F610A) and E2 binding mutants (V567A/
D570A, L593A/I598A) were unaffected by addition of
compoundA (Fig. 2A, cf. lanes 4, 8, 12, and 16). TWEAK, on the
other hand, effectively reduced the levels of wild-type cIAP1
and that of the RINGmutants (Fig. 2A, cf. lanes 3, 7, 11, and 15).
This result shows, surprisingly, that neither cIAP1 E2 binding
nor cIAP1 RING dimerization are required for TWEAK Fn14-
mediated cIAP1 loss.
Degradation of TRAF2 following TWEAK stimulation
depends upon whether a soluble or membrane-bound mimic
form (Fc TWEAK) of the ligand is used to stimulate cells (31).
Both forms of the ligand, however, drive cIAP1 andTRAF2 into
aTritonX-100-insoluble fraction (10, 31).We therefore further
examined whether recruitment of TRAF2 to the insoluble frac-
tion was dependent on cIAP1 RING dimerization. The F610A
mutant also supported loss of TRAF2 from the supernatant
(supplemental Fig. S2A, lane 12) and prevented accumulation
in the pellet fraction (supplemental Fig. S2A, lane 16) in a sim-
ilar manner to the wild-type cIAP1. This is evident even in the
uninduced samples where there is, nevertheless, significant
expression of cIAP1 (supplemental Fig. S2A, lanes 9 and
11, long exposure).
To further test the importance of the cIAP1-TRAF2 interac-
tion in TWEAK signaling we reconstituted cIAP1/ MEFs
with a TRAF2 binding mutant of cIAP1, E64A/R65A. If the
cIAP-TRAF2 interaction is required for TWEAK-induced deg-
radation of cIAP1, such a mutant would be expected to be
resistant to TWEAK-induced degradation but not to IAC-in-
duced degradation. Consistent with our previous observations
in TRAF2 knock-out cells (10), the TRAF2 binding mutant of
cIAP1 was resistant to TWEAK-induced degradation, yet still
able to undergo compoundA-triggered degradation (Fig. 2B, cf.
lanes 7 and 8). Together these results demonstrate that cIAPs
can be degraded by two distinct processes and that only IAC-
induced degradation depends on the integrity of the RING
domain of cIAPs.
TNF has been reported to induce RING-mediated transloca-
tion of TRAF2 to a detergent-insoluble compartment through a
Ubc13-dependent mechanism (32). Ubc13 mediates the
attachment of Lys63-linked polyubiquitin chains to substrate
proteins (33).We therefore tested whether Ubc13 was required
for degradation of cIAP1 andTRAF2 followingTWEAKand/or
compound A. shRNA knockdown of Ubc13 levels by70% did
not, however, affect degradation of either cIAP1 or TRAF2 fol-
lowing TWEAK treatment (supplemental Fig. S2B). Consistent
with a role for UbcH5 in compoundA-mediated cIAP degrada-
tion, knock-down of Ubc13 also had no effect on the degrada-
tion of cIAP1 by compound A (supplemental Fig. S2B).
RING Functions Are Required for cIAP1 to Inhibit Activation
of Non-canonical NF-B—Following TWEAK stimulation or
treatment with compound A, the non-canonical NF-B path-
way is activated through loss of cIAP1 and stabilization of NIK
(a Lys48 ubiquitin substrate of cIAP1 (6, 7)). In cIAP1 or TRAF2
knock-out cells NIK levels are therefore constitutively high (6,
12) and can be reduced by re-introduction of wild-type cIAP1
(Fig. 3A) or TRAF2 (18), respectively. To test the importance of
E2 binding andRINGdimerization in this particular function of
cIAP1 we therefore induced cIAP1 mutants in cIAP1/ cells
and Western blotted for NIK levels. As a positive control for
detection of NIK, we treated D645 cells with compound A,
which promotes cIAP1 degradation and NIK accumulation
FIGURE 2. RING mutants of cIAP1 distinguish between TWEAK- and compound A-triggered loss of cIAP1. A, inducible cIAP1/ MEFs used in Fig. 1B
were inducedwith 5 nM 4HT for 16 h and incubatedwith orwithout 100 ng/ml of TWEAK or 500 nM compoundA. DISC lysateswere separated using SDS-PAGE
and analyzed by Western blot for cIAP1 levels. B, cIAP1 TRAF2 interaction is required for TWEAK-induced degradation of cIAP1. cIAP1 knock-out MEFs were
reconstituted with inducible lentivirus expressing a TRAF2 interactingmutant (E64A/R65A (2)) as described in the legend to Fig. 1B. Cells were inducedwith 5
nM 4HT for 16 h and incubated in the presence or absence of 100 ng/ml of TWEAK or 500 nM compound A for 16 h and analyzed as in A.
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(Fig. 3A, lanes 9 and 10). cIAP1/MEFs have constitutively
high levels of NIK that are reduced by induction of wild-type
cIAP1 (Fig. 3A, lanes 1 and 2). Induction of either a dimer-
ization or E2 binding mutant of cIAP1 had no effect on the
endogenous levels of NIK (Fig. 3A, cf. lane 2 with lanes 4, 6,
and 8).
Stabilization of NIK leads to phosphorylation and proteaso-
mal processing of NF-B2 p100 to the p52 subunit resulting in
translocation of the p52-RelB heterodimer to the nucleus. To
further investigate the ability of cIAP1mutants to regulate non-
canonical NF-B we assayed for the processing of p100 to p52.
Induction of wild-type cIAP1 for 72 h reduced the levels of p52
and increased p100 levels (Fig. 3B, cf. lanes 1 and 2). The weak
E2 binding mutant (L593A) was also able to reset the p100-p52
ratio in a similar way to wild-type cIAP1, but neither the dimer
mutant nor the other E2 binding mutants of cIAP1 were effec-
tive in resetting the p100:p52 ratio (Fig. 3B, lanes 4, 6, 8, and 12).
Taken together, these results indicate that the basal activation
of the non-canonical NF-B pathway requires cIAP1 RING
function.
These results demonstrate that RING mutants expressed in
cIAP1/cIAP2/ MEFs cannot regulate the non-canonical
NF-B pathway. We therefore wondered whether they might
inhibit wild-type cIAP function. To address this question, and
extend our observations to other cell types, we inducibly
expressed cIAP1 and mutants thereof in Kym1 and D645 cell
lines. Both D645 and Kym1 cells express detectable levels of
endogenous cIAP1 and therefore NIK levels are constitutively
FIGURE3. cIAP1RINGfunctionsare required for cIAP1 to inhibit constitutivenon-canonicalNF-Band for full activation followingTWEAK.A, cells used
in Figs. 1 and 2were incubatedwith or without 5 nM 4HT for 16 h, lysed, and the lysates separated by SDS-PAGE. NIK levels were assayed byWestern blot using
a NIK antibody. B, RINGmutants of cIAP1 cannot prevent the constitutive processing of p100 to p52 observed in cIAP1/MEFs. Cells were inducedwith 5 nM
4HT for 72h, lysed inDISC lysis buffer, andanalyzedbyWesternblottingusingap100antibody that recognizesbothp100andp52.C, D645andKym1cellswere
infected with a lentivirus expressing inducible mouse wild-type cIAP1 or a construct containing point mutations in the E2 binding interface (L593A/I598A).
Polyclonal populationswere inducedwith 10 nM 4HT for 16 h and then treatedwith orwithout 500 nM compoundA for 4 h. Cells were lysed in DISC lysis buffer
supplementedwith protease inhibitors and NEM. Lysates were separated using SDS-PAGE and analyzed byWestern for NIK and p100/p52 and cIAP1.D, D645
and Kym1 cells were infected with a lentivirus expressing inducible mouse wild-type cIAP1 or a construct containing point mutations in the dimerization
interface (F610A). Polyclonal populations were inducedwith 10 nM 4HT for 16 h and then treatedwith or without 500 nM compound A for 4 h. Cells were lysed
inDISC lysis buffer supplementedwithprotease inhibitors andNEM. Lysateswere separatedusing SDS-PAGE and analyzedbyWesternblots forNIK, p100/p52,
and cIAP1.
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low. Induction of wild-type cIAP1 or any of our RINGmutants
in D645 and Kym1 cells had no discernible effect on the regu-
lation of NIK by endogenous cIAP1 or the basal processing of
NF-B2 to p52 (E2 mutants, Fig. 3C, lanes 2, 5, and 8; dimer
mutants, Fig. 3D, lanes 5 and 11). This indicates that overex-
pressed RING mutants did not act as strong dominant nega-
tives to inhibit wild-type cIAP1 function over the time course of
this assay. We further tested our mutants by depleting endog-
enous cIAP1 with an IAC. As described previously, IAC treat-
ment of Kym1 and D645 cells resulted in degradation of wild-
type cIAP1, NIK levels rose and p100 was processed to p52 (6)
(Fig. 3, C and D). Consistent with our observations in MEFs,
none of our RING mutants were able to prevent the activation
of non-canonicalNF-B following IAC treatment, further dem-
onstrating their lack of activity in different experimental
settings.
TWEAK Further Increases NF-B Activity in cIAP DKO and
TRAF2 KO Cells—It has been proposed that several members
of the TNFSF, including TWEAK, have the ability to activate
non-canonical NF-B simply by promoting degradation of
TRAF2 and cIAP1 (10, 34). This model of TWEAK signaling
would therefore predict that TWEAK would be unable to pro-
mote further activation of non-canonical NF-B in either
TRAF2 or cIAP1 and -2 double knock-out cells. To test this
prediction we incubated cIAP1/cIAP2/ MEFs with
TWEAK and monitored NIK levels and p100 processing at 4
and 16 h post-TWEAK stimulation. Surprisingly, NIK levels
increased, as did p100 processing, even in cIAP DKO MEFs,
although this was clearly less than in wild-type MEFs and also
delayed. Reconstitution of the DKO MEFs with wild-type
cIAP1 reduced the basal level of NIK and rescued the ability of
the knock-out cells to respond to TWEAK at the early 4-h time
FIGURE 4. TWEAK further increasesNF-Bactivity in cIAPDKOandTRAF2KOcells.A, cIAP1 and cIAP2DKOMEFswere immortalizedwith SV40 large T and
reconstitutedwith inducible cIAP1 constructs aspreviously described for cIAP1/ cells. Cellswere induced for 72hwith10nM4HTand treatedwithorwithout
100 ng/ml of TWEAK for the indicated times. Cells lysates were analyzed as described in the legend to Fig. 3, A and B. B, binding to TRAF2 is required for cIAP1
to inhibit non-canonical NF-B activation. TRAF2/MEFs were immortalized with SV40 large T and infected with inducible TRAF2 constructs that contained
either pointmutations or a deletion in theCIM (13). Cellswere induced for 72hwith 5nM4HT and treatedwith orwithout 100ng/ml of TWEAK for the indicated
times. Cell lysateswere analyzed byWestern blot for p100, p52, NIK, and TRAF2 levels. C, cIAPDKOMEFs and TRAF2/MEFs constitutively activate NF-B that
can be further increased by addition of TWEAK. Wild-typeMEFs, cIAP DKOMEFs, or TRAF2 KOMEFs immortalized with SV40 large T containing lentivirus were
infected with a lentivirus containing a enhanced green fluorescent protein NF-B reporter. Cells were treated with 100 ng/ml of TWEAK or TNF for 16 h. Cells
were analyzed by flow cytometry for fluorescence in the FL-1 (green) channel.
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point (Fig. 4A, lanes 7–9). Neither the E2 binding mutant nor
the dimer mutant were able to rescue and, if anything, even
responded less to TWEAK than the DKOMEFs (Fig. 4A, lanes
10–15).
To further explore the finding of increased NIK stabiliza-
tion and p100 to p52 processing in cIAP DKO MEFs we
looked at TWEAK signaling in TRAF2 knock-out MEFs. We
recently identified a cIAP interacting motif (CIM) in TRAF2
that is required for cIAPs to interact with TRAF2. In partic-
ular, deletion of amino acids 283–293 from TRAF2 pre-
vented the binding of cIAP to TRAF2 and point mutation of
both Glu292 and Glu294 showed reduced TRAF2-cIAP inter-
action (18). Consistent with the cIAP DKO MEFs,
TRAF2/ MEFs were also still able to respond to TWEAK
by elevating NIK levels and increasing processing of p100,
albeit significantly less well than wild-type cells. Reconstitu-
tion of the knock-out MEFs with wild-type TRAF2 restored
signaling similar to wild-type cells, as did reconstitution with
the weak cIAP binding mutant (Fig. 4B, cf. lanes 1–3, 7–9,
and 10–12). TRAF2/MEFs reconstituted with the TRAF2
CIM mutant, however, behaved almost identically to the
knock-out cells (Fig. 4B, cf. lanes 4–6 and 13–15). To further
analyze the increase following TWEAK, we infected the cIAP
DKO and TRAF2/ cells with an NF-B-GFP reporter.
Both the cIAP DKO and TRAF2/ cells displayed constitu-
tively high basal NF-B activity compared with the wild-type
MEFS (Fig. 4C). A clear shift in GFP fluorescence can be seen
following TWEAK (black) or TNF (gray) stimulation in wild-
type MEFs, with a slightly larger shift post-TNF treatment.
TNF is a strong activator of canonical NF-B and this most
likely explains the different response compared with the
weaker shift seen with TWEAK. Consistent with the West-
ern results, both cIAP DKO and TRAF2/MEFs showed an
increase in NF-B activity, above the high basal activity, fol-
lowing TWEAK or TNF stimulation (Fig. 4C). This assay is,
however, unable to distinguish between canonical and non-
canonical NF-B activity, and although it is consistent with
the Western analysis must be interpreted carefully. Taken
together these results demonstrated that although cIAP and
TRAF2 are important regulators of NF-B, TWEAK can
enhance the non-canonical pathway in cIAP and TRAF2
independent manners.
RING Mutants of cIAP1 Severely Impair the Activation of
Canonical NF-B following TNF Treatment—TNF is a well
studied activator of canonical NF-B. TNF binding to
TNF-R1 in MEFs results in p65-RelA phosphorylation
within 5 min and almost complete IB degradation within
15 min, thereby allowing p50-p65 translocation into the
nucleus (35). Loss of IB is only transient because IB is a
transcriptional target of NF-B, and its levels are restored
within 60 min of TNF addition. cIAPs are thought to be
important regulators of this pathway, because loss of both
cIAP1 and cIAP2 inhibits TNF-induced activation of NF-B
(14, 16). Using cIAP1 and cIAP2 DKO MEFs reconstituted
with inducible cIAP1 mutants we therefore decided to test
the contribution of the RING domain to TNF activation of
NF-B. Consistent with previous reports that used different
methods to deplete both cIAPs (14, 16), TNF-induced deg-
radation of IB was significantly reduced and delayed in
two independent cIAP1 and cIAP2 DKO MEF lines com-
pared with wild-type MEFs (Fig. 5A, cf. lanes 1–6 with lanes
7–12, and lanes 13–18 (14, 16)). It is noteworthy that TNF-
induced IB degradation still occurs in cIAPDKOMEFs, so
activation of NF-B is not abolished, but rather reduced and
delayed, and that both cIAP DKO MEF lines had high basal
levels of phosphorylated p65. Wild-type cIAP1 was able to
partially restore IB degradation in response to TNF in
cIAP DKOMEFs, with degradation occurring within 15 min
and not rebounding within 60 min as in wild-typeMEFs (Fig.
5B, compare lanes 1–5 with lanes 6–10). Wild-type cIAP1
also reduced basal p65 phosphorylation and allowed TNF to
promote increased p65 phosphorylation in these cells. The
dimerization mutant was ineffective at promoting IB deg-
radation, and degradation of IB occurred with similar
kinetics to the parental DKOMEF line (Fig. 5B, lanes 11-15).
Similarly, reconstitution of cIAP1 E2 binding mutants into
cIAP DKOMEFs resulted in partial restoration of IB deg-
radation with the weak E2 binding mutant (Fig. 5C, lanes
11–15) and no restoration with the strong E2 mutant (Fig.
5C, lanes 16–20). Furthermore, expression of our strong E2
binding mutant in D645 cells did not interfere with TNF-
induced IB degradation, measured at 15 and 30 min
(supplemental Fig. 3B, cf. lanes 3 and 4 and 7 and 8). This lack
of activity is consistent with the inability of our RING
mutants to change the kinetics of IB degradation induced
by TNF in cIAP DKO MEFs.
Differences in the protein level in Western blots, even if
performed multiple times, are not completely reliable mea-
sures of signaling responses. Therefore to further examine the
effect of wild-type cIAP1 and cIAP1 mutants on TNF-induced
NF-B we looked at p65 translocation to the nucleus by immu-
nofluorescence microscopy. p65 translocates to the nucleus
within 20min after addition ofTNFandbegins to exit by 60min
in wild-type MEFs, and neither translocation is affected by sin-
gle deletion of either cIAP1 or cIAP2 (Fig. 5D). We considered
the possibility that the RING mutants reintroduced into the
single cIAP1/ MEFs might function as dominant negatives
that could interfere with the activity of the endogenous cIAP2.
However, these mutants did not affect p65 translocation in
cIAP1/ cells (supplemental Fig. 3A). Therefore we restricted
our analysis to cIAPDKO cells that show amarked delay in p65
translocation. Consistent with the Western analysis (Fig. 5,
A–C), deletion of both cIAP1 and cIAP2 significantly delayed
translocation of p65 to the nucleus, which occurred at 60
min instead of the usual 20 min (Fig. 5E). Reconstitution of
cIAP1 and cIAP2 DKO MEFs with wild-type cIAP1 restored
normal p65 nuclear translocation following TNF treatment
(Fig. 5E), whereas reconstitution with a cIAP1 mutant that
could no longer form RING dimers or with mutants that are
defective in recruiting E2 did not rescue the DKO phenotype
except in the case of the weaker, V567A/D570A E2 binding
mutant (Fig. 5E). Therefore, both dimerization and E2 bind-
ing are essential for normal canonical NF-B activation fol-
lowing TNF stimulation.
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Dimerization and E2 Recruitment Are Required for cIAP1 to
ProtectMEFs fromTNF-inducedCell Death—MEFs depleted of
cIAP1 by knock-out or IAC are sensitive to exogenous TNF,
and re-introduction of wild-type cIAP1 is able to provide sub-
stantial protection (6). The mechanism for cIAP1-mediated
protection against TNF is not completely clear, particularly if
the fact that p65 translocation occurs normally in these cells,
is taken into account. To try and dissect the functions of cIAP1
that might be required to protect cells from TNF we tested
TRAF2 binding, the dimer and E2 binding mutants for their
ability to protect against TNF. Consistent with our previous
results (6) addition of TNF to cIAP1/ cells resulted in80%
cell death and this high percentage of cell death was reduced to
20% upon induction of wild-type cIAP1 (Fig. 6A). None of the
mutants tested were capable of providing protection against
TNF. Together, these results demonstrate that cIAP1 RING
functions are critical for protection from TNF killing.
cIAP1 RING dimerization and E2 binding are, however, not
required for loss of cIAP1 following TWEAK. To analyze
involvement of the cIAP1 RING domain in TWEAK or
TWEAK/TNF-mediated cell death, we tested whether our
mutants interfered with TWEAK signaling in cells with endog-
FIGURE5.RINGmutantsof cIAP1 inhibit TNF-inducedcanonicalNF-Bactivation.A, wild-typeMEFs andMEFsderived from twocIAP1/2double knock-out
embryos immortalized with SV40 large T antigen were incubated with or without 100 ng/ml of Fc-TNF for the indicated times. Lysates were made and
separated using SDS-PAGE and blotted for phosphorylated p65 and IB. B, a RING dimer mutant of cIAP1 is unable to restore normal TNF-induced p65
phosphorylation and IBdegradation in cIAP1 cIAP2DKOMEFs. Polyclonal populations described in the legend to Fig. 3were incubatedwith orwithout 5 nM
4HT for 16hprior to incubationwith 100ng/ml of Fc-TNF for the indicated times.C, E2-bindingmutants of cIAP1 are unable to restore normal TNF-inducedp65
phosphorylation and IBdegradation in cIAP1 cIAP2DKOMEFs. Polyclonal populations described in the legend to Fig. 3were incubatedwith orwithout 5 nM
4HT for 16 h prior to incubation with 100 ng/ml of Fc-TNF for the indicated times.D, p65 translocates normally in cIAP1/ and cIAP2/MEFs following TNF.
Wild-type, cIAP1/, or cIAP2/MEFs transformed with SV40T were grown on coverslips overnight and treated with TNF for the indicated times. Cells were
fixed immediately and stainedwith p65 antibody as described under ”Experimental Procedures“ and viewed under a40 fluorescencemicroscope objective.
E, RING functions of cIAP1 are critical for normal TNF-induced translocation of p65 to the nucleus. Cells used in Fig. 4, B and C, were grown on coverslips
overnight and treated as in D.
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enous wild-type cIAP expression. Neither the dimerization nor
the E2 bindingmutants interfered with TWEAK/TNF-induced
cell death in D645 cells or TWEAK-triggered apoptosis in
Kym1 cells (Fig. 6, B and C). However, because TWEAK-in-
duced death requires the production of autocrine TNF (6, 36) it
is difficult to distinguish between the effects of cIAPs at the
TNF and TWEAK signaling receptors in TWEAK-mediated
cell death. In conclusion, although the RING domain of cIAP1
is required to protect cells from the cytotoxic actions of TNF,
the cIAP1 RING is, however, not required for cell death
induced by the TNFSF ligand TWEAK.
DISCUSSION
cIAP1 and its less well characterized paralog cIAP2 are
important E3 ligases whose ubiquitylation activities are still
incompletely understood. Our recent experiments have
focused on the function of cIAP1 and show that it is important
in regulating both TWEAK-Fn14 and TNF-TNF-R1 signaling
(6, 10). Using the cIAP2 RING UbcH5 crystal structure we
designed point mutations in the predicted RING dimer and E2
binding interfaces of cIAP1 (5) and tested the ability of these
mutants to rescue signaling in cIAP1/ and cIAP1/-
cIAP2/ (DKO) MEFs.
FIGURE 6. cIAP1-mediated protection against TNF-induced apoptosis in MEFs is dependent on dimerization and E2 association. A, cells from Fig. 1B
were left induced or un-inducedwith 5 nM 4HT for 72 h and treatedwith 100 ng/ml of TNF for 24 h. Cells were stainedwith propidium iodide (PI) and analyzed
by flow cytometry. B, cells from Fig. 3, C and D, were induced with 10 nM 4HT for 24 h and treated with 100 ng/ml of TWEAK or TNF for 24 h. Cells were stained
with PI and analyzed by flow cytometry. C, cells were analyzed as in B. Error bars represent S.E., n 3.
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IAP antagonist compounds target cIAP1, cIAP2, and XIAP
are presumed to activate the E3 ligase activity of the cIAPs. As
predicted from this model, using the experimental system
described above, we show that loss of cIAP1 E2 binding pre-
vents IAP antagonist-induced ubiquitylation and degradation.
Although a precise function for RING dimerization has not
been discovered a RING dimer mutant of cIAP1 is also pro-
tected from IAP antagonist-induced degradation, as previously
reported (18).
Several groups have shown that treatment of cells with IACs
or small interfering RNAs that deplete cIAPs prevents TNF-
induced RIPK1 modification (14–17), suggesting that cIAPs
are the E3 ligases that ubiquitylate RIPK1. Consistent with the
hypothesis that cIAPs are key E3 ligases for RIPK1, cIAP DKO
MEFs do not ubiquitylate RIPK1 following TNF treatment (17).
Our cIAP1 F610A RING dimer mutant was also incapable of
rescuing RIPK1 ubiquitylation following TNF signaling in
cIAP1/cIAP2/ MEFs (17) supporting the idea that this
mutant affects not only autoubiquitylation, but also substrate
ubiquitylation.
Using these mutants we then tested their ability to regulate
TWEAK and TNF signaling. Following TWEAK stimulation,
TRAF2 and cIAP1 are recruited to Fn14 and then relocate to a
detergent-insoluble compartment (10). Translocation probably
precedes degradation in the lysosome because translocation,
but not degradation, occurs in some cell lines if a soluble form
of TWEAK is used (31). Lysosomal degradation and transloca-
tion may also be dependent upon A20 because TWEAK-in-
duced TRAF2 degradation was abolished in A20/ cells (11).
Other reports have also observed nonproteasomal degradation
of TRAF2 and cIAP1 downstream of TNFSF receptors such as
TNF-R2 and CD30 (37, 38). Such results suggest that the
requirements for cIAP RING function might be different
between IAP antagonist-induced degradation and in TWEAK
signaling. However, we were surprised to find that neither E2
binding nor RINGdimer formationwere required forTWEAK-
induced cIAP and TRAF2 translocation. Consistent with our
previous results in TRAF2/ cells (18) a cIAP1 mutant that
cannot bind TRAF2 is not degraded following TWEAK stimu-
lation. These results strongly support a model for TWEAK sig-
naling that requires cIAP recruitment by TRAF2 to Fn14 but
that does not require cIAP RING function for TRAF2 and cIAP
degradation. We considered the possibility that TRAF2 func-
tions via the Lys63 E2, Ubc13, to promote cIAP1 and TRAF2
degradation, but knock-down of UBC13 had no discernible
affect on this process. These results are in line with a recent
paper (39) that demonstrates that TRAF2 is unable to interact
with UBC13. Indirectly our data also provides support for our
earlier finding and other more recent ones that TRAF2 and
cIAP1 degradation following TWEAK signaling does not occur
via a proteasomal pathway (10, 11). Several groups have shown
that signaling through TNFSF receptors such as CD40, TNF-
R2, and BAFFR induce cIAP-dependent proteasome degrada-
tion of TRAF2 (9, 40, 41) and/or TRAF3 (9, 41). The differences
between these results might reflect either the different ligand/
receptor systems, or even the type of ligand used (34). We have
used a mimic of the membrane-bound form of TWEAK, Fc-
TWEAK, and it is known that soluble and membrane-bound
forms of TNFSF ligands have different signaling capabilities
(31, 42). The key issue to addresswithTWEAKwill therefore be
which form of ligand is used in which physiological signaling
situation.
TWEAK is a strong activator of non-canonical NF-B (43).
IAP antagonist compounds also activate the non-canonical
NF-B pathway by depleting IAPs, leading to stabilization of
NIK and processing of NF-B2 to p52 (6–9). Furthermore, sev-
eral recent reports have shown that loss of cIAPs, TRAF2, or
TRAF3 is sufficient to result in constitutive activation of non-
canonical NF-B (6–9, 12, 44–46). These results have led to
the proposal that cIAPs, TRAF2, and TRAF3 together form a
complex that targets NIK to the proteasome and that cIAPs are
the Lys48 E3 ligases that ubiquitylate NIK to induce its degra-
dation (7–9, 16). Our data are consistent with this model
because cIAP1/cIAP2/ MEFs have high basal levels of
NIK that are reduced if these cells are reconstituted with wild-
type cIAP1 but not a RING dimer or E2 binding mutant. The
RING-dependent regulation of NIK also seems to be conserved
across cell types, as bothD645 andKym1 cell lines exhibited the
same RING-dependent regulation of NIK by cIAP1.
Based on this model of cIAP-TRAF2-TRAF3 regulation of
NIK, we have proposed that TWEAK activates non-canonical
NF-B simply by promoting the translocation and degradation
of TRAF2 and cIAPs thereby allowingNIK levels to accumulate
(10). If this proposal is correct, however, TWEAK would be
unable to promote enhanced non-canonical activation in cIAP
DKO cells or TRAF2 KO cells. However, whereas cIAP and
TRAF2 KO cells were clearly significantly impaired in their
ability to activate non-canonical NF-B above the increased
basal levels in these knock-out cells, some further stabilization
of NIK occurred following TWEAK stimulation. This shows
that NIK levels are not solely regulated by cIAPs and TRAF2
and that other mechanisms exist to regulate NIK levels. This
cIAP-TRAF2 independent pathway can be regulated by
TWEAK/FN14 signaling. It is possible that as these cells were
generated from cells that lost cIAPs or TRAF2 during embry-
onic development that some adaptation has occurred, and the
extent to which this alternative pathway of regulating NIK lev-
els exists in normal cells is therefore still an open question.
There is also substantial data showing that cIAPs regulate
TNF-induced activation of the canonical NF-B pathway. For
example, reduction in the levels of both cIAP1 and cIAP2 was
shown to prevent TNF-induced IB degradation (14, 16). Loss
of cIAPs induced by IAP antagonist treatment also severely
impairs RIPK1 ubiquitylation. Thus cIAPs might contribute to
TNF-induced NF-B by providing a platform for recruitment
of TAK1 and IKK complexes. Consistent with this idea, we pre-
viously published (18) that a TRAF2 CIM mutant that cannot
bind cIAPs could not restore normalNF-Bor ubiquitylation of
RIPK1 in response to TNF in TRAF2 and TRAF5 DKO MEFs
(18). In this work we confirmed and extended these earlier
results by demonstrating that cIAP1 and cIAP2 DKO MEFs
display delayed and reduced IB degradation compared with
wild-type cells in response to TNF as well as a significant delay
in p65 translocation to the nucleus. This is consistent with ours
and others (18, 47) recently published data demonstrating that
TRAF2 and TRAF5 DKO MEFs have impaired canonical
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NF-B activity in response to TNF. Possibly, in the absence of
the major E3 ligases a backup signaling mechanism is initiated.
This sort of flexibility seems inherent to the TNF-R1 signaling
complex because, in addition to the data presented here it has
recently been shown that neither TRADD nor RIPK1 are
required for TNF-induced NF-B (13, 48, 49).
Reintroduction of wild-type cIAP1, but not dimerization or
E2 binding mutants, restored the normal NF-B response in
cIAP DKO MEFs compared with wild-type MEFs. Therefore
consistent with previous observations we show that cIAP1 is a
critical regulator of TNF-induced NF-B, and that RING
dimerization and E2 binding are required to control this
activation.
cIAP1, in addition to regulating TNF-induced NF-B, also
provides protection that is independent of its NF-B function.
This protective signal is dependent on cIAP1 RING dimeriza-
tion and E2 recruitment, and it is possible therefore that the
protective signal involves limiting the death inducing activity of
RIPK1 that has recently been demonstrated (50–52).
In summary, by reconstituting cIAP1 knock-out and cIAP1
and cIAP2 double knock-out cells with point mutants of cIAP1
we have tested the requirements for E2 binding and RING
dimer formation in several cIAP1-regulated signaling path-
ways. Our data provide further support for models proposing
that the E3 ligase function of cIAP1 is required to limit basal
activation ofNF-B2 by promoting proteasomal degradation of
NIK. However, data also demonstrates that other cIAP-
TRAF2-independent pathways exist to regulate NIK levels and
that TWEAK can increase NIK levels even in cIAP1 and cIAP2
double knock-out cells. Our data supports the proposal that the
E3 ligase activity of cIAPs is important in regulating TNF-in-
duced NF-B, but also show that TNF can induce a delayed
NF-B response even in cIAP1 and cIAP2 double knock-out
cells. Surprisingly we find that both E2 binding and RING
dimerization are dispensable in proximal TWEAK signaling
events. These data therefore provide further support for the
proposal that TWEAK induces a non-proteasomal degradation
of TRAF2 and cIAP1. It will now be interesting to see how this
pathway is regulated, how prevalent this signaling mechanism
is in TNFSF signaling, and finally how the form of ligand affects
these proximal signaling events.
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